Merck (MRK) Operating Income (2009 - 2026)
Merck (MRK) posted quarterly Operating Income of -$7.7 billion for Q1 2026, down 411.15% year-over-year from $2.5 billion in Q1 2025, and down 262.69% quarter-over-quarter from -$2.1 billion in Q4 2025.
Merck (MRK) Operating Income (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Operating Income for 18 consecutive years, with -$7.7 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 411.15% year-over-year to -$7.7 billion; the TTM figure through Mar 2026 stood at -$5.5 billion (down 208.46% YoY), while the FY2025 annual figure was $4.7 billion, down 1.22% from the prior year.
- Operating Income fell to -$7.7 billion in Q1 2026 per MRK's latest filing, from -$2.1 billion in the prior quarter.
- Across five years, Operating Income topped out at $2.9 billion in Q3 2025 and bottomed at -$9.4 billion in Q2 2023.
- Historically, Operating Income has averaged -$794.4 million across 5 years, with a median of $10.0 million in 2024.
- Annual changes were most pronounced in 2023 — Operating Income slumped 3553.51% — and 2025, when it jumped 28800.0%.
- Merck's Operating Income stood at -$368.0 million in 2022, then slumped by 1519.02% to -$6.0 billion in 2023, then surged by 105.74% to $342.0 million in 2024, then plunged by 723.1% to -$2.1 billion in 2025, then tumbled by 262.69% to -$7.7 billion in 2026.
- Business Quant data shows MRK's Operating Income at -$7.7 billion in Q1 2026, -$2.1 billion in Q4 2025, and $2.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 16.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.08 Bn |
| Mar 31, 2026 | -7.73 Bn |
| Dec 31, 2025 | -2.13 Bn |
| Sep 30, 2025 | 2.89 Bn |
| Jun 30, 2025 | 1.44 Bn |
| Mar 31, 2025 | 2.48 Bn |
| Dec 31, 2024 | 342.00 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Jun 30, 2024 | 2.26 Bn |
| Mar 31, 2024 | 2.13 Bn |
| Dec 31, 2023 | -5.96 Bn |
| Sep 30, 2023 | 1.36 Bn |
| Jun 30, 2023 | -9.36 Bn |
| Mar 31, 2023 | -276.00 Mn |
| Dec 31, 2022 | -368.00 Mn |
| Sep 30, 2022 | -351.00 Mn |
| Jun 30, 2022 | 271.00 Mn |
| Mar 31, 2022 | -519.00 Mn |
| Dec 31, 2021 | 35.00 Mn |
| Sep 30, 2021 | 1.82 Bn |